Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Reviewed by TrialFinderData Editorial Team · Updated

8 clinical trials · 8 recruiting · OTHER

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta has 8 clinical trials registered on ClinicalTrials.gov, with 8 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta\'s Trial Portfolio

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

8 of Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta's 8 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta's research footprint spans Cerebral Amyloid Angiopathy (2 trials), Glioma (1), and Glioma of Brain (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

is the largest single phase in Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta's portfolio at 88% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

RECRUITINGNCT07547163

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy...

The study aims to assess the direct patient-reported perception (PROs) of individuals affected by IDH-mutant, grade 2 gliomas undergoing radiotherapy or pharmacological treatment...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 901 location
GliomaGlioma of BrainLow Grade Glioma of Brain+2
RECRUITINGNCT07233941

Neuropsychological Profile Characterization in Patients With Migraine: Cognitive Functioning and Psychological Variables

The overall objective is to define the neuropsychological profile of patients with migraine and evaluate its association with: psychological outcome measures (anxiety-depressive...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 1501 location
MigraineMigraine Disease
RECRUITINGNCT06724029

Neurosurgical Outcome Network

The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 450020 locations
AneurysmsArteriovenous MalformationsCavernomas+20
RECRUITINGNCT07427940

Omic Profile in Autism Spectrum Disorder: From Cellular Level Towards Future Treatments

This is an interventional non pharmacological study in pediatric patientis affected by Autism Spectrum Disorder. It ams to create a collection of iPSCs and hiNSCs derived from...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 1001 location
Autism Spectrum Disorder
RECRUITINGNCT04880356

Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.

General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 1001 location
Inherited DiseaseRare DiseasesMetabolic Disease+3
RECRUITINGNCT06935578

RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular...

Cerebrovascular diseases (CVDs) are one leading cause of morbidity and mortality worldwide. Despite intensive investigations, more than 30% of strokes remain of undetermined...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 50017 locations
CADASILCADASIL (Diagnosis)Moya Moya Disease+5
RECRUITINGNCT06933212

Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.

The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 861 location
Cerebral Amyloid AngiopathyCAA - Cerebral Amyloid Angiopathy
RECRUITINGNCT04204642

SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)

Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 5001 location
Cerebral Amyloid Angiopathy

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta have on ClinicalTrials.gov?

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta has 8 clinical trials registered on the federal ClinicalTrials.gov registry, of which 8 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta study?

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta's registered trials cover 20 conditions on ClinicalTrials.gov, led by Cerebral Amyloid Angiopathy (2 trials), Glioma (1 trial), Glioma of Brain (1 trial), low-grade-glioma-of-brain (1 trial), low-grade-gliomas (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 8 trials tracked for Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta.